Lemborexant
 | |
| Systematic (IUPAC) name | |
|---|---|
|
(1R,2S)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | 1369764-02-2 |
| ATC code | None |
| PubChem | CID 56944144 |
| ChemSpider | 34500836 |
| Chemical data | |
| Formula | C22H20F2N4O2 |
| Molar mass | 410.417 g/mol |
| |
| |
Lemborexant (INN) (code name E-2006) is a dual antagonist of the orexin OX1 and OX2 receptors which is under development by Eisai for the treatment of insomnia.[1] [2][3] As of December 2014, it is in phase II clinical trials.[4]
See also
References
- ↑ Christopher, John A (2014). "Small-molecule antagonists of the orexin receptors". Pharmaceutical Patent Analyst 3 (6): 625–638. doi:10.4155/ppa.14.46. ISSN 2046-8954.
- ↑ Cristoph Boss, Catherine Ross (2015). "Recent Trends in Orexin Research – 2010 to 2015". ScienceDirect. doi:10.1016/j.bmcl.2015.05.012.
- ↑ Boss, Christoph (2014). "Orexin receptor antagonists – a patent review (2010 to August 2014)". Expert Opinion on Therapeutic Patents 24 (12): 1367–1381. doi:10.1517/13543776.2014.978859. ISSN 1354-3776.
- ↑ AdisInsight. "Lemborexant". Springer. Retrieved 2015-05-23.
External links
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Tuesday, April 05, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.